Erratum: Targeted gene silencing using RGD-labeled chitosan nanoparticles (Clinical Cancer Research (2010) 16 (3910-3922) DOI: 10.1158/1078-0432.CCR-10-0005);Targeted gene silencing using RGD-labeled chitosan nanoparticles

Clinical Cancer Research

Volumn 16, Issue 15, 2010, Pages 3910-3922

  Han, Hee Dong ^a   Mangala, Lingegowda S ^a   Lee, Jeong Won ^a,c   Shahzad, Mian M K ^a,b   Kim, Hye Sun ^a,d   Shen, Deyu ^a   Nam, Eun Ji ^a,e   Mora, Edna M ^a,g,h   Stone, Rebecca L ^a   Lu, Chunhua ^a   Lee, Sun Joo ^a,f   Roh, Ju Won ^a,i   Nick, Alpa M ^a   Lopez Berestein, Gabriel ^a   Sood, Anil K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Kwandong University College of Medicine   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

^f Konkuk University Hospital   (South Korea)

^g UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^h UNIVERSITY OF PUERTO RICO   (Puerto Rico)

ⁱ Dongguk University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; CHITOSAN; DOCETAXEL; NANOPARTICLE; PROTEIN FAK; PROTEIN PLXDC1; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 77955113615     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-21-2119     Document Type: Erratum

References (51)

1. Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 2007;59:75-86.
2. Merritt WM, Lin YG, Han LY, et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 2008;359:2641-50.
3. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009;8:129-38.
4. Merritt WM, Lin YG, Spannuth WA, et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst 2008;100:359-72.
5. Halder J, Kamat AA, Landen CN, Jr., et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 2006; 12:4916-24.
6. Thaker PH, Han LY, Kamat AA, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 2006;12:939-44.
7. Zhang C, Jugold M, Woenne EC, et al. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res 2007;67:1555-62.
8. Pirollo KF, Chang EH. Targeted delivery of small interfering RNA: approaching effective cancer therapies. Cancer Res 2008;68: 1247-50.
9. Wolfrum C, Shi S, Jayaprakash KN, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 2007;25: 1149-57.
10. Han HD, Song CK, Park YS, et al. A chitosan hydrogel-based cancer drug delivery system exhibits synergistic antitumor effects by combining with a vaccinia viral vaccine. Int J Pharm 2008;350: 27-34.
11. Seo SH, Han HD, Noh KH, Kim TW, Son SW. Chitosan hydrogel containing GMCSF and a cancer drug exerts synergistic anti-tumor effects via the induction of CD8(+) T cell-mediated anti-tumor immunity. Clin Exp Metastasis 2009;26:179-87.
12. Zhang HM, Chen SR, Cai YQ, et al. Signaling mechanisms mediating muscarinic enhancement of GABAergic synaptic transmission in the spinal cord. Neuroscience 2009;158:1577-88.
13. Temming K, Schiffelers RM, Molema G, Kok RJ. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist Updat 2005;8:381-402.
14. Xie J, Shen Z, Li KC, Danthi N. Tumor angiogenic endothelial cell targeting by a novel integrin-targeted nanoparticle. Int J Nanomedicine 2007;2:479-85. (Pubitemid 350047790)
15. Park JH, Kwon S, Nam JO, et al. Self-assembled nanoparticles based on glycol chitosan bearing 5β-cholanic acid for RGD peptide delivery. J Control Release 2004;95:579-88.
16. Ho MH, Wang DM, Hsieh HJ, et al. Preparation and characterization of RGD-immobilized chitosan scaffolds. Biomaterials 2005;26: 3197-206.
17. Kim JH, Kim YS, Park K, et al. Self-assembled glycol chitosan nanoparticles for the sustained and prolonged delivery of antiangiogenic small peptide drugs in cancer therapy. Biomaterials 2008;29: 1920-30.
18. Mitra A, Mulholland J, Nan A, McNeill E, Ghandehari H, Line BR. Targeting tumor angiogenic vasculature using polymer-RGD conjugates. J Control Release 2005;102:191-201.
19. Mitra A, Coleman T, Borgman M, Nan A, Ghandehari H, Line BR. Polymeric conjugates of mono- and bi-cyclic αVβ3 binding peptides for tumor targeting. J Control Release 2006;114:175-83.
20. Han HD, Shin BC, Choi HS. Doxorubicin-encapsulated thermosensitive liposomes modified with poly(N-isopropylacrylamideco- acrylamide):drugrelease behavior and stability in the presence of serum. Eur J Pharm Biopharm 2006;62:110-6.
21. Lu C, Kamat AA, Lin YG, et al. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin Cancer Res 2007;13:4209-17.
22. Mangala LS, Zuzel V, Schmandt R, et al. Therapeutic targeting of ATP7B in ovarian carcinoma. Clin Cancer Res 2009;15:3770-80.
23. Hajitou A, Trepel M, Lilley CE, et al. A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell 2006;125:385-98.
24. Mintz PJ, Cardo-Vila M, Ozawa MG, et al. An unrecognized extracellular function for an intracellular adapter protein released from the cytoplasm into the tumor microenvironment. Proc Natl Acad Sci U S A 2009;106:2182-7.
25. Kim TJ, Ravoori M, Landen CN, et al. Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res 2007;67: 9337-45.
26. Landen CN, Jr., Chavez-Reyes A, Bucana C, et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005;65:6910-8.
27. Landen CN, Jr., Lu C, Han LY, et al. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst 2006;98:1558-70.
28. Landen CN, Kinch MS, Sood AK. EphA2 as a target for ovarian cancer therapy. Expert Opin Ther Targets 2005;9:1179-87.
29. Spannuth WA, Sood AK, Coleman RL. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol 2008;5: 194-204. (Pubitemid 351493679)
30. Donninger H, Bonome T, Radonovich M, et al. Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene 2004;23:8065-77.
31. Apte SM, Fan D, Killion JJ, Fidler IJ. Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma. Clin Cancer Res 2004;10:897-908.
32. Baker CH, Kedar D, McCarty MF, et al. Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. Am J Pathol 2002;161:929-38. (Pubitemid 34988380)
33. Hood JD, Bednarski M, Frausto R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science 2002;296: 2404-7.
34. Oba M, Fukushima S, Kanayama N, et al. Cyclic RGD peptide-conjugated polyplex micelles as a targetable gene delivery system directed to cells possessing αvβ3 and αvβ5 integrins. Bioconjug Chem 2007;18:1415-23.
35. Kudo Y, Siriwardena BS, Hatano H, Ogawa I, Takata T. Periostin: novel diagnostic and therapeutic target for cancer. Histol Histopathol 2007;22:1167-74.
36. Sood AK, Coffin JE, Schneider GB, et al. Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am J Pathol 2004;165:1087-95.
37. Landen CN, Kim TJ, Lin YG, et al. Tumor-selective response to antibody-mediated targeting of αvβ3 integrin in ovarian cancer. Neoplasia 2008;10:1259-67.
38. Lu C, Bonome T, Li Y, et al. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res 2007;67:1757-68.
39. Mangala LS, Han HD, Lopez-Berestein G, Sood AK. Liposomal siRNA for ovarian cancer. Methods Mol Biol 2009;555:29-42.
40. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008;7:771-82.
41. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A 2007;104:15549-54.
42. McNeeley KM, Karathanasis E, Annapragada AV, Bellamkonda RV. Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors. Biomaterials 2009;30: 3986-95.
43. Bartlett DW, Davis ME. Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug Chem 2007;18:456-68.
44. Lv H, Zhang S, Wang B, Cui S, Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 2006;114: 100-9.
45. Akhtar S, Benter I. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv Drug Deliv Rev 2007;59:164-82.
46. Hollins AJ, Omidi Y, Benter IF, Akhtar S. Toxicogenomics of drug delivery systems: exploiting delivery system-induced changes in target gene expression to enhance siRNA activity. J Drug Target 2007; 15:83-8.
47. Akhtar S, Benter IF. Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest 2007;117:3623-32.
48. Katas H, Alpar HO. Development and characterisation of chitosan nanoparticles for siRNA delivery. J Control Release 2006;115: 216-25. (Pubitemid 44559708)
49. Liu X, Howard KA, Dong M, et al. The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. Biomaterials 2007;28:1280-8.
50. Mangala L, Han HD, Lu C, et al. In vivo vascular and tumor cell gene silencing with chitosan nanoparticles in ovarian carcinoma. AACR Meeting Abstracts 2008;2008:5613.
51. Gillan L, Matei D, Fishman DA, Gerbin CS, Karlan BY, Chang DD. Periostin secreted by epithelial ovarian carcinoma is a ligand for α(V)β(3) and α(V)β(5) integrins and promotes cell motility. Cancer Res 2002;62:5358-64.